so.cardoso
TL2 · Chennai
Contributes reviews on supplier material. Based in Chennai.
Joined 11 September 2024 · last posted 2d
80 posts, newest first. Showing up to 150.
-
Journal club: what we got wrong in an earlier session Replied, post #123 · Evidence › Journal club · 26 Jul 2026 · 0 likes I read post #121 twice before replying, because I had assumed the opposite. The baseline characteristics table is the single most useful page for the questions that get…
-
What is genuinely unknown about long-term amylin agonism Replied, post #67 · Compounds › Cagrilintide & amylin analogues · 21 Jul 2026 · 14 likes Fine by me. I had wanted a stronger conclusion and there is not one available.
-
Reading a home test result without over-claiming Replied, post #126 · Analytics › Home & field testing · 19 Jul 2026 · 4 likes Post #122 put the caveat in the right place and I want to underline it. Nothing available at home distinguishes a correct sequence from a closely related incorrect one.…
-
Revisiting: The best-written scientific paper you have read Replied, post #95 · Lounge › Off topic · 16 Jul 2026 · 14 likes That is true everywhere. The reference material that gets used is the material that answers a question you have at the moment you have it, and glamour has nothing to do…
-
Muscle cramps: the ordinary causes before the exotic ones — a second dataset Replied, post #52 · Practice › Side effects · 15 Jul 2026 · 8 likes What I would want before treating Muscle cramps as settled: the method, the sample, and whether anyone tried to find the opposite result. Two of the three are usually…
-
Revisiting: Why the absence of controlled human data on BPC-157 matters more than people… Replied, post #26 · Compounds › Repair & healing peptides · 12 Jul 2026 · 25 likes Where the absence of controlled human data discussion usually stalls is that nobody wants to say "I do not know" and everyone is willing to say "it varies". Those are…
-
A structured critique template this community uses — a second dataset Replied, post #33 · Evidence › Study critique · 9 Jul 2026 · 24 likes Post #29 put the caveat in the right place and I want to underline it. A note on how structured critique template gets discussed rather than on structured critique…
-
Second pass at: Reading a trial's population section before its results Replied, post #3 · marked as the solution · Evidence › Trials · 9 Jul 2026 · 12 likes I read the opening post twice before replying, because I had assumed the opposite. A trial that answers a slightly different question from the one you have is the…
-
Pooling trials with different estimands Replied, post #81 · Evidence › Meta-analyses · 8 Jul 2026 · 3 likes Narrowing post #78, because the general version has more than one answer. Study quality and weighting: some meta-analyses weight all studies equally; others weight by…
-
Insurance and replacement policies, compared Replied, post #58 · Sourcing › Logistics · 2 Jul 2026 · 0 likes A request rather than an answer: could whoever has the primary source for insurance and replacement policies post it? I have seen the claim three times this month and…
-
Does dual agonism explain the effect size, or is it dose? Replied, post #40 · Compounds › Tirzepatide · 16 Jun 2026 · 0 likes Where I part company with post #38, and it is a narrow parting. The published pharmacokinetics show dose proportionality across the studied range, which means dose…
-
Journal club: indirect comparison between two programmes, defended and attacked Replied, post #87 · Evidence › Journal club · 15 Jun 2026 · 11 likes What I can speak to on indirect comparison is narrow, so I will keep it narrow rather than generalising from it. Beyond that boundary I do not know.
-
Coming back to: Time to steady state after a dose increase Replied, post #75 · Pharmacology › Pharmacokinetics · 12 Jun 2026 · 24 likes Adding the measurement that post #72 says would settle it. Area under the curve is the exposure measure that matters for most effects in this class. Peak concentration…
-
Micronutrient adequacy at low total intake Replied, post #56 · Nutrition & Training › Protein & intake · 11 Jun 2026 · 5 likes Where intake has fallen a long way, protein is usually the first thing to fall because it is the least appealing macronutrient when appetite is reduced.
-
[2026 update] Area percent versus weight percent: the confusion that causes most arguments Replied, post #53 · Analytics › HPLC & UHPLC · 5 Jun 2026 · 26 likes What I would check first on Area percent versus weight percent is whether the thing being measured moved or whether the way of measuring it moved. Those look identical…
-
Prescription portability between countries Replied, post #49 · Access › International · 31 May 2026 · 8 likes On post #46 — agreed on the reasoning, with one qualification. Customs practice varies between entry points within the same country, which is why two people in the same…
-
Revisiting: What pooling buys you and what it destroys Replied, post #36 · Evidence › Meta-analyses · 28 May 2026 · 0 likes What I can speak to on pooling buys is narrow, so I will keep it narrow rather than generalising from it. Beyond that boundary I do not know.
-
Validating a calculator against hand arithmetic Replied, post #21 · Data & Tools › Calculators · 28 Apr 2026 · 18 likes Answering the question post #17 raises rather than the one it answers. What I would check first on validating a calculator against hand is whether the thing being…
-
List price versus negotiated price versus what you pay Replied, post #50 · Access › Pricing · 12 Apr 2026 · 0 likes List prices versus negotiated prices: the price a pharmaceutical company publishes and the price an insurance company or pharmacy actually pays differ substantially.…
-
Spike-and-recover accuracy for a peptide assay Replied, post #39 · Analytics › Method validation · 8 Apr 2026 · 28 likes The limit of quantitation determines what the impurity table can honestly contain. Peaks below it can be reported as detected and cannot be reported as a number.
-
A plateau that disappeared when I changed how I measured Replied, post #30 · Outcomes › Progress reports · 7 Apr 2026 · 12 likes Post #28 put the caveat in the right place and I want to underline it. A plateau over two weeks is usually measurement. A plateau over two months is usually energy…
-
Coming back to: Half-life, steady state, and accumulation worked through Replied, post #5 · Pharmacology › Pharmacokinetics · 3 Apr 2026 · 0 likes Useful. I had the fact and not the reason, which turns out to be the important half.
-
Second pass at: Identical chromatograms across two different lots Replied, post #92 · Sourcing › Red flags · 25 Mar 2026 · 0 likes Identical chromatograms has a well-known answer and a correct answer, and the interesting work is establishing that they are the same. Nobody has done that here yet.
-
Revisiting: Language barriers in accessing a prescription abroad Replied, post #146 · Access › International · 5 Mar 2026 · 0 likes Post #145 is right about the mechanism and I think understates the practical bit. Language barriers in accessing is a question about a distribution, not about a value,…
-
Research-use-only labelling: what it means and what it does not Replied, post #94 · Sourcing › Regulatory · 28 Jan 2026 · 29 likes A label change is a regulatory event with a date and a document. Citing the document is what makes a claim about labelling checkable. The disagreement above is smaller…
-
Reconstitution volumes that produce round numbers, tabulated Replied, post #34 · Practice › Reconstitution · 28 Jan 2026 · 0 likes Post #32 describes the usual case. This is about the unusual one. Do not shake. Swirl, or leave it. Vigorous agitation introduces air and shear, and neither helps a…
-
Second pass at: Pregnancy and pregnancy planning: contraindication and washout Replied, post #110 · Clinical › Special populations · 26 Jan 2026 · 0 likes Everything in post #106 holds. The case it does not cover is the one I have. Adding a small correction to the Pregnancy and pregnancy planning summary above rather than…
-
Coming back to: A community side-effect dataset, with its response rate and biases Replied, post #18 · Data & Tools › Datasets · 24 Jan 2026 · 0 likes How to contribute: if you have longitudinal data you want to add, the format is simple: date, measurement, context. Contact the maintainer of the specific dataset.
-
Pregnancy and pregnancy planning: contraindication and washout Replied, post #19 · Clinical › Special populations · 20 Jan 2026 · 7 likes Answering the question post #17 raises rather than the one it answers. Pregnancy and pregnancy planning is one of those subjects where the general answer and the answer…
-
Request: a diff view for wiki revisions — the long version Replied, post #97 · Meta › Feature requests · 10 Jan 2026 · 5 likes This settles it for me, at least until somebody posts a reason it should not.
-
Lyophilisation and why the cake looks the way it does Replied, post #27 · Pharmacology › Formulation chemistry · 29 Nov 2025 · 6 likes Counter-ion exchange from trifluoroacetate to acetate is a purification step with a cost, and material sold without it retains TFA. That affects mass balance and can…
-
Sequence verification for an obscure compound: how it is done — what changed since Replied, post #88 · Compounds › Other compounds · 26 Nov 2025 · 3 likes Solubility varies far more across this subcategory than within the incretins. A compound that needs a specific diluent or a specific pH is not being difficult; it has a…
-
Availability by country, dated, with primary sources — one year on Replied, post #2 · Access › International · 25 Nov 2025 · 24 likes Import rules for personal use: what you can import for personal use depends on your country's rules, not on where it is sold. Checking your country's rules before…
-
Reading an interaction checker output critically Replied, post #49 · Practice › Interactions · 22 Nov 2025 · 1 like I have no financial interest in anything named in this thread and I want to say so before I comment on reading an interaction checker output, because it is the sort of…
-
The headache that turns out to be dehydration Replied, post #52 · Nutrition & Training › Hydration & electrolytes · 10 Nov 2025 · 19 likes Answering the question post #49 raises rather than the one it answers. On headache I would separate what is worth knowing from what is worth acting on. The first list…
-
New subcategory: rationale and scope Replied, post #123 · Meta › Announcements · 26 Oct 2025 · 1 like Coming back to post #121, because the follow-up matters more than the original answer. Where the new subcategory discussion usually stalls is that nobody wants to say…
-
Run-in periods and the population they select Replied, post #13 · Evidence › Trials · 23 Oct 2025 · 21 likes I read post #12 twice before replying, because I had assumed the opposite. Absolute and relative effects answer different questions. Write down the event rate in each…
-
How to ask about something you suspect is a bad idea Replied, post #14 · Start Here › How to Ask · 6 Oct 2025 · 30 likes Answering the question post #10 raises rather than the one it answers. Disagreeing with an answer you got: cite what you disagree with, say what contradicts it, and ask…
-
Cagrilintide's dosing interval and the pharmacokinetics behind it Replied, post #93 · Compounds › Cagrilintide & amylin analogues · 5 Oct 2025 · 0 likes The monoisotopic mass sits near 3749.9 Da, and the same caveat applies as everywhere else: a mass consistent with the proposed structure is a necessary condition and…
-
Citing a preprint in a maintained document: our rule and its reasoning — does this still… Replied, post #87 · Evidence › Preprints · 2 Oct 2025 · 31 likes Two sentences on Citing a preprint and then I will stop, because the rest is speculation and the thread is better without mine. What is documented is narrow. What is…
-
[2026 update] Does dual agonism explain the effect size, or is it dose? Replied, post #32 · Compounds › Tirzepatide · 30 Sep 2025 · 24 likes Post #29 answers the question as asked. The question underneath it is different. Dual agonism is worth one more sentence than it usually gets, and the sentence is the…
-
Adolescents: a distinct evidence base — one year on Replied, post #20 · Clinical › Special populations · 28 Sep 2025 · 5 likes What I would tell a new member reading about Adolescents for the first time: the confident posts are not the reliable ones, and the reliable ones are longer.
-
Second pass at: Programming during a large energy deficit Replied, post #13 · Nutrition & Training › Resistance training · 20 Sep 2025 · 3 likes Recovery: heavier training on a energy deficit and on a compound that slows gastric emptying requires attention to recovery (sleep, nutrition, stress). Recovery…
-
Documentation that materially improves an appeal's chances Replied, post #3 · Access › Insurance & coverage · 15 Sep 2025 · 2 likes I had written a reply contradicting the opening post and deleted it. Here is what survived. A peer-to-peer review is available in many systems and is frequently more…
-
Washout: how long is long enough, and for what purpose Replied, post #65 · Pharmacology › Pharmacokinetics · 11 Sep 2025 · 0 likes Coming back to post #64, because the follow-up matters more than the original answer. Metabolism for peptide drugs is proteolytic rather than hepatic in the usual…
-
Substitution between formats during a shortage Replied, post #45 · Access › Shortages · 26 Aug 2025 · 31 likes Picking up post #42: that is the part I would want checked first. Manufacturer allocation decisions during a shortage are commercial and are rarely explained, which is…
-
Why "any advice?" is the least effective ending for a post — the long version Replied, post #42 · Start Here › How to Ask · 22 Aug 2025 · 1 like I read post #40 twice before replying, because I had assumed the opposite. Timeline questions need the timeline. Dates, in order, with what happened on each. "A while…
-
Coming back to: Lurking for two months before posting: was that the right call? Replied, post #29 · Start Here › Welcome · 22 Aug 2025 · 0 likes The Lounge is a real category rather than a dumping ground. The sourcing rule still applies there, which surprises people, but the register is looser and nobody minds a…
-
Older adults, sarcopenia risk, and the trade-off nobody quantifies — the long version Replied, post #12 · Clinical › Special populations · 21 Aug 2025 · 0 likes I disagree with the framing of Older adults above, and I think it is a substantive disagreement rather than a terminological one. Setting out why, so it can be checked.…
-
Temperature loggers worth the money — the long version Replied, post #23 · Devices › Cold chain · 11 Aug 2025 · 1 like This follows post #20 rather than contradicting it. Summer routes and winter routes are genuinely different problems, and a supplier that changes its packing between…
-
Coming back to: Resolution and tailing factor: real acceptance criteria Replied, post #32 · Analytics › HPLC & UHPLC · 10 Aug 2025 · 1 like Following this. I have the same question and no better information than the first post.
-
Revisiting: List price versus negotiated price versus what you pay Replied, post #14 · Access › Pricing · 6 Aug 2025 · 0 likes Larger orders shift risk as well as price, because more of your material then comes from one lot.
-
What a documentation review can and cannot tell you Replied, post #59 · Sourcing › Independent verification · 3 Aug 2025 · 28 likes I read post #57 twice before replying, because I had assumed the opposite. Repeat determination on the same product line months apart is the measurement that speaks to…
-
Fatigue in the first month: how much is the drug and how much is intake — what changed… Replied, post #8 · Practice › Side effects · 28 Jul 2025 · 29 likes Reading rather than contributing, but this is the most useful thread I have found on it.
-
Titles that describe the question, not the situation Replied, post #45 · Start Here › How to Ask · 10 Jul 2025 · 17 likes Reframing titles slightly, because I think the disagreement is about the question rather than the answer. If the question is "does it happen", yes. If it is "how…
-
Coming back to: Why semaglutide solutions can look faintly opalescent and when that… Replied, post #10 · Compounds › Semaglutide · 29 Jun 2025 · 2 likes My understanding of semaglutide solutions is a few years old and may have been superseded. If it has been, I would genuinely like to know rather than keep repeating it.
-
[2026 update] An appeal that failed, and what I would do differently Replied, post #125 · Access › Insurance & coverage · 15 Jun 2025 · 6 likes Worth separating two things that post #123 runs together. Distinguishing three things in the appeal discussion that keep getting used interchangeably: the observation,…
-
Price changes over 2025 and 2026, tabulated and dated Replied, post #9 · Access › Pricing · 12 Jun 2025 · 8 likes Price variation between pharmacies: identical prescriptions can cost different amounts at different pharmacies because pharmacies negotiate individually with insurers…
-
A 5 mg vial and a 0.25 mg dose: the arithmetic in full — the long version Replied, post #119 · Practice › Reconstitution · 29 May 2025 · 1 like How much of the diluent volume the powder itself displaces: for a small peptide vial, the powder volume is negligible. For a larger vial or a kit with multiple…
-
DXA precision and the least significant change for lean mass — the long version Replied, post #90 · Outcomes › Body composition · 24 May 2025 · 26 likes Where I part company with post #88, and it is a narrow parting. Where a scan disagrees with the mirror over a short period, the scan's precision limits are usually the…
-
Washout: how long is long enough, and for what purpose Replied, post #25 · Pharmacology › Pharmacokinetics · 10 May 2025 · 11 likes A pharmacokinetic model fitted to trial data describes the population studied. Applying it to somebody outside the enrolled range is an extrapolation, and the model…
-
A claim built entirely on a subgroup analysis Replied, post #10 · marked as the solution · Evidence › Study critique · 29 Apr 2025 · 13 likes Taking post #8 at face value and following it one step further. A run-in period that excludes non-responders before randomisation changes what the trial is estimating.…
-
Follow-up: What other technical communities get right that we do not Replied, post #50 · Lounge › Off topic · 27 Mar 2025 · 19 likes Lounge question, no agenda: does anyone else keep a physical notebook for this rather than a file? Mine is more use than anything I have typed, and I cannot entirely…
-
About the Journal club category Replied, post #7 · Evidence › Journal club · 24 Mar 2025 · 29 likes This follows post #4 rather than contradicting it. The most common failure mode is spending fifty minutes on the effect size and ten on the population. Reversing that…
-
Journal club: STEP 4 and what a withdrawal design can prove — one year on Replied, post #47 · Evidence › Journal club · 19 Mar 2025 · 15 likes Thank you — that answers what I came here to find out.
-
Adjudicated events and why the definition matters — the long version Replied, post #55 · Evidence › Trials · 19 Mar 2025 · 22 likes Picking up post #54: that is the part I would want checked first. Second-hand on Adjudicated events, so weight it accordingly — someone whose method I trust told me…
-
Second pass at: Gauge and length selection for subcutaneous injection Replied, post #41 · Devices › Syringes & needles · 13 Mar 2025 · 3 likes Narrowing post #40, because the general version has more than one answer. Two things can be true about Gauge and length selection at once: the mechanism is plausible…
-
Coming back to: Why the cheapest option is often not the cheapest Replied, post #13 · Access › Pricing · 11 Mar 2025 · 25 likes Post #9 put the caveat in the right place and I want to underline it. Nothing here is financial advice and none of it is a route to a transaction.
-
Revisiting: What a well-designed human trial of a secretagogue would look like Replied, post #57 · Compounds › Secretagogues & GH axis · 29 Jan 2025 · 2 likes Coming back to post #55, because the follow-up matters more than the original answer. GHRH analogues versus ghrelin mimetics are often conflated but they are different…
-
Fixed versus detachable needles: the trade-offs Replied, post #86 · Devices › Syringes & needles · 2 Jan 2025 · 22 likes Worth separating two things that post #82 runs together. The quoted dead-volume figures for common configurations vary between manufacturers and the ordering is stable:…
-
Research-use-only status: what it means legally and practically — a second dataset Replied, post #52 · Compounds › Other compounds · 30 Dec 2024 · 0 likes Nothing to add, except that this is the answer I would give if asked.
-
Molecular mass of semaglutide and why the figure differs between sources — does this… Replied, post #29 · Compounds › Semaglutide · 20 Dec 2024 · 3 likes Solutions of semaglutide can look faintly opalescent without anything being wrong. Visible particulate, fibres or frank cloudiness are a different observation entirely…
-
Coming back to: Cost per delivered dose, which is the number that matters Replied, post #4 · Access › Pricing · 15 Dec 2024 · 0 likes Cost per week at a maintenance dose is the figure most people actually want and least often calculate.
-
Promotion criteria, and the one that stops most nominations Replied, post #135 · Documentation › Doc review · 8 Dec 2024 · 0 likes Objections are genuinely wanted at this stage, because a bad promotion is much harder to undo than a bad reply. If anyone has run this properly I would rather read that…
-
Why pulsatile secretion matters for interpreting secretagogue claims — a second dataset Replied, post #25 · Compounds › Secretagogues & GH axis · 28 Nov 2024 · 1 like The pulsatile character of endogenous growth hormone release is why a secretagogue and exogenous growth hormone are not interchangeable, and why a single measured level…
-
When a preprint is the best available evidence and we say so — a second dataset Replied, post #6 · Evidence › Preprints · 19 Nov 2024 · 0 likes Adding the measurement that post #5 says would settle it. Where numbers change between preprint and published version, the changes are not random. They tend toward a…
-
Hypertension improvement and when medication needs revisiting — a second dataset Replied, post #117 · Clinical › Comorbidities · 28 Oct 2024 · 18 likes The confident answers on Hypertension improvement and the well-sourced answers are not the same answers, which is the most useful thing I have learned reading this…
-
Converting between mg/mL and units per dose, both directions Replied, post #17 · Practice › Reconstitution · 11 Sep 2024 · 8 likes The decimal-point error: computing 5 mg / 2 mL as 0.25 mg/mL instead of 2.5 mg/mL is the most common arithmetic error in this subcategory. The habit that catches it:…
-
Air bubbles in a subcutaneous injection: the honest risk assessment Replied, post #3 · Practice › Administration · 30 Aug 2024 · 8 likes Pinch or no pinch: the decision depends on needle length and on your own anatomy. A longer needle (8 mm and up) reaches subcutaneous tissue easily without a pinch. A…
-
Second pass at: Retatrutide dose escalation in the published trials Replied, post #75 · Compounds › Retatrutide · 21 Jul 2024 · 5 likes Adding thanks rather than a view. I do not have a view worth the space.